CNBX Pharmaceuticals Inc. (CNBX) Cash & Equivalents (2013 - 2026)

CNBX Pharmaceuticals (CNBX) has 14 years of Cash & Equivalents data on file, last reported at $9487.0 in Q2 2026.

• Quarterly Cash & Equivalents fell 30.49% year-over-year to $9487.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $9487.0 (down 30.49% YoY) and the FY2025 annual result came in at $15111.0, down 42.8% from the prior year.
• Cash & Equivalents declined to $9487.0 in Q2 2026, from $12154.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $231637.0 in Q1 2022 to a low of $7703.0 in Q4 2025.
• A 5-year average of $57130.7 and a median of $40646.5 in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 97.25% — and 2023, when it jumped 278.0%.
• Tracing CNBX's Cash & Equivalents over 5 years: stood at $21600.0 in 2022, then jumped by 278.0% to $81647.0 in 2023, then plunged by 78.76% to $17339.0 in 2024, then tumbled by 55.57% to $7703.0 in 2025, then climbed by 23.16% to $9487.0 in 2026.
• The last three Cash & Equivalents figures came in at $9487.0 (Q2 2026), $12154.0 (Q1 2026), and $7703.0 (Q4 2025), per Business Quant data.